ADAM9 and non-small cell lung carcinoma: Greater effort should be taken to test more novel and valuable prognostic and predictive biomarkers, such as ADAM9 and HDGF (21), in order to use more simple but accurate methods, to aid decision-making in regard to NSCLC patients receiving personalized adjuvant chemotherapy or not.